ESRRB and ovarian serous adenocarcinoma: Median survival of patients with serous ovarian cancers expressing high levels of ERRβ was 1058 days, whereas women with tumors with low expression of ERRβ had a median survival of 1938 days (hazard ratio (HR) 2.74; 95% CI 1.06–7.11) (Fig. 4a).